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Abstract
Background: Although a large number of epidemiological studies have examined the role of
aspirin in the chemoprevention of colon cancer and other solid tumors, there is a limited body of
research focusing on the association between aspirin and lung cancer risk.
Methods: We conducted a hospital-based case-control study to evaluate the role of regular
aspirin use in lung cancer etiology. Study participants included 868 cases with primary, incident lung
cancer and 935 hospital controls with non-neoplastic conditions who completed a comprehensive
epidemiological questionnaire. Participants were classified as regular aspirin users if they had taken
the drug at least once a week for at least one year.
Results: Results indicated that lung cancer risk was significantly lower for aspirin users compared
to non-users (adjusted OR = 0.57; 95% CI 0.41–0.78). Although there was no clear evidence of a
dose-response relationship, we observed risk reductions associated with greater frequency of use.
Similarly, prolonged duration of use and increasing tablet years (tablets per day × years of use) was
associated with reduced lung cancer risk. Risk reductions were observed in both sexes, but
significant dose response relationships were only seen among male participants. When the analyses
were restricted to former and current smokers, participants with the lowest cigarette exposure
tended to benefit most from the potential chemopreventive effect of aspirin. After stratification by
histology, regular aspirin use was significantly associated with reduced risk of small cell lung cancer
and non-small cell lung cancer.
Conclusions: Overall, results from this hospital-based case-control study suggest that regular
aspirin use may be associated with reduced risk of lung cancer.
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Background
Regular use of aspirin and other non-steroidal anti-in-
flammatory dugs (NSAIDs) has been consistently associ-
ated with reduced risk of colorectal cancer and adenoma
[1–4], possibly due to NSAID-related inhibition of pros-
taglandin synthesis, enhancement of cellular immune re-
sponse, or induction of apoptosis [5–8]. A number of
epidemiological studies have investigated the potential
protective effect of NSAIDs with respect to other cancer
sites. There is some evidence that regular and prolonged
NSAID use is associated with reduced risk of cancers of the
esophagus [3,9,10] stomach [3,9,11], ovary [12,13], and
female breast [14–16].
Although there is a growing body of epidemiological evi-
dence on the role of aspirin and other NSAIDs in the che-
moprevention of lung cancer (Table 1.; [14,17–23]),
about half of these studies published to date were not spe-
cifically designed to investigate this association [17–
19,21]. In a randomized trial aimed at examining the ef-
fect of aspirin in the prevention of cardiovascular disease
in male physicians, Peto et al [17] first noted lower lung
cancer mortality rates in the aspirin intervention group
compared to the placebo group. Two subsequent cohort
studies demonstrated associations with regular [18] or fre-
quent aspirin use [19] among women, but not men. In
contrast, in a prospective analysis of the NHANES I fol-
low-up study, Schreinemachers & Everson [14] reported
lower incidence of lung cancer only among men classified
as recent aspirin users. Rosenberg [20] observed no strong
evidence for a chemopreventive role of aspirin in a hospi-
tal-based case-control study; whereas Langman et al. [21],
in a record-based case-control study, reported a borderline
significant risk reduction associated with frequent pre-
scriptions of NSAIDs. Most recently, results from a case-
control study, nested within the NYU Women's Health
Study [22], indicated that women classified as regular as-
pirin users were at a marked, and statistically significant,
reduced risk of non-small cell lung cancer (NSCLC) com-
pared to women classified as non-users; however, no sig-
nificant associations were observed for all histological
types combined. Another recent case-control study inves-
tigated the effect of aspirin on lung cancer risk in a sample
of heavy smokers [23]. Results indicated that daily aspirin
use was strongly associated with reduced risk; this effect
was apparent for both men and women. We conducted a
hospital-based case-control study to further investigate
the overall association between aspirin use and lung can-
cer risk, and to add to the limited body of evidence on the
potential effect modifying roles of tumor histology and
cigarette smoking on the chemopreventive role of aspirin
in lung tumorigenesis.
Methods
Study population
The study population included individuals who received
medical services at the Roswell Park Cancer Institute (RP-
CI) between 1982 and 1998, and who agreed to complete
a comprehensive epidemiological questionnaire. In-
formed consent was obtained from all participants. The
case group consisted of 868 individuals with primary, in-
cident lung cancer, identified from the RPCI tumor regis-
try and Diagnostic Index. Controls included 935
individuals, randomly selected from a pool of 7957 eligi-
ble individuals, who received medical services at RPCI for
non-neoplastic conditions. These participants came to
RPCI with a suspicion of neoplastic disease, but were not
diagnosed with either benign or malignant conditions.
The most frequently utilized services among the controls
were carried out in the breast clinic (13%), dermatology
clinic (12%), gastrointestinal clinic (15%), and sarcoma/
melanoma clinic (15%). The remaining controls were
seen in a variety of clinics at our institute, including gyne-
cological oncology, hematology, head and neck, radio-
therapy, and urology; however the proportion of controls
seen at these clinics was less than five percent of all control
participants. Controls were frequency matched to cases on
sex and five-year age intervals.
Questionnaire
All participants completed the Patient Epidemiology Data
System (PEDS) questionnaire, which is offered to all new
patients as part of the admission process, and is returned
by approximately 50 percent of new patients. The 16-page
instrument covers information on tobacco and alcohol
consumption, family history of cancer, occupational and
environmental exposures, reproductive and medical his-
tories, and diet. The instrument also assesses aspirin use
relevant to the period prior to the onset of disease. Specif-
ically, the instrument queried: 'If you are currently ill, in-
dicate how often you took these medications before the
illness'. Participants provided information on how many
times a week and for how many years they took aspirin.
Participants who reported aspirin use at least once a week
for one year were classified as regular aspirin users. Dos-
age of use was assessed by comparing participants who
were classified as non-users to participants who reported
that they had taken aspirin either one to six times per
week or seven or more times per week. Duration of use
was evaluated by comparing non-users to participants
who took aspirin for six months to ten years or more than
ten years. We also evaluated a combined measure of dos-
age and duration by computing tablet years (tablets per
day × years of use). Reason for analgesic use was unavail-
able for these analyses.
Statistical analyses
Results
Descriptive characteristics of the study population are
shown in Table 2. Due to the matching procedures, thereBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/31
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were no differences between cases and controls with re-
spect to age and sex. Cases were significantly less likely
than controls to have obtained a college education (p <
0.001). As expected, cases were more likely than controls
to be former and current smokers (p < 0.001), and to have
had more packyears of cigarettes (p < 0.001).
Table 3 displays the association between aspirin use and
lung cancer risk in the total sample, as well as among fe-
males and males separately. Compared to nonusers, regu-
lar aspirin use was associated with a significant reduction
in risk of lung cancer in the total study sample (adjusted
OR = 0.57; 95% CI 0.41–0.78), as well as among female
(adjusted OR = 0.52; 95% CI 0.29–0.95) and male (ad-
justed OR = 0.62; 95% CI 0.43–0.90) participants. Higher
dosage of aspirin (seven or more tablets per week) was sig-
nificantly associated with risk in the total sample (adjust-
ed OR = 0.58; 95% CI 0.41–0.82) and among male
participants (adjusted OR = 0.56; 95% CI 0.37–0.83).
Prolonged duration of use (11 or more years) was not as-
sociated with a significant reduction in risk in either the
total sample, nor among the subgroups defined by sex.
However, self-reported aspirin use of one to 10 years was
associated with a significantly lower risk of lung cancer in
all groups. Among male participants, there was evidence
of a dose response relationship with lower risk as a func-
tion of longer duration of use (p < 0.01). Risk of lung can-
cer was significantly reduced in relation to increasing
tablet years in the total sample (p < 0.001) and in males
(p < 0.01). We further explored these associations by re-
stricting the sample to current and former smokers, who
were divided into tertiles of packyears of cigarettes
smoked. As can be seen in Table 4, risk estimates for the
exposure categories described above were generally below
the null among all smoking groups. However, statistically
significant risk reductions and dose-response relation-
ships were only observed for participants in the lower ter-
tile of packyear distribution (1–34 packyears). Table 5
displays the association between regular aspirin use and
risk of histology-specific lung cancer. Significant risk re-
Table 1: Aspirin use and lung cancer risk – summary of published studies.
Study (reference) Year (place) Design Study sample Key results
Peto et al.[17] 1988 (UK) Randomized Trial 5139 British physicians: aspirin inter-
vention group (n = 3429) vs. placebo 
group (n = 1710)
Lung cancer death rates lower in aspirin group (7.4/
10.000 person years) vs. placebo group (11.6/10.000 
person years)
Paganini-Hill 
et al.[18]
1989 (US) Cohort study 13 987 retirement community resi-
dents; 111 lung cancer cases after 
6.5 years of follow-up
No evidence of lower incidence of lung cancer 
among male daily aspirin users (RR = 1.35); Lower 
incidence of lung cancer among female daily aspirin 
users (RR = 0.29)
Thun et al.[19] 1993 (US) Cohort study Cancer Prevention Study II: 635,031 
US residents; 6 year follow-up
No evidence of lower mortality from respiratory 
cancers in association with aspirin use among men; 
Lower respiratory cancer mortality among women 
using aspirin 1–15 times/month (RR = 0.73; 95 % CI 
0.56–0.97)
Schreinemachers 
& Everson [14]
1994 (US) Cohort study NHANES I follow-up: 12,668 US 
residents; 189 respiratory cancers 
after 12.4 years (mean) of follow-up
Significantly lower incidence of lung cancer among 
men using aspirin in past 30 days (RR = 0.55; 95% CI 
0.38–0.81); No evidence of lower lung cancer inci-
dence among women using aspirin (RR = 1.40; 95% 
CI 0.74–2.66)
Rosenberg[20] 1995 (US) Hospital-based 
case-control 
study
1110 lung cancer cases; 1181 cancer 
controls and 4906 non-cancer con-
trols
Non-significant risk reduction associated with aspi-
rin use when case group compared to cancer con-
trols (RR = 0.80; 95% CI 0.60–1.20), but not 
apparent when compared to non-cancer controls 
(RR = 1.00; 95% CI 0.70–1.40)
Langman[21] 2000 (UK) Record-linkage 
case control 
study
2560 lung cancer patients and 7643 
controls identified from general 
practice research data base
Non-significant risk reduction associated with 7+ 
prescriptions of NSAIDs 1–3 years prior to diagno-
sis (OR = 0.84; 95% CI 0.69–1.02)
Akhmedkhanov 
et al.[22]
2002 (US) Nested case-con-
trol study
81 female lung cancer patients and 
808 controls selected from the NYU 
Women's Health Study
Non significant risk reduction between regular aspi-
rin use and overall lung cancer (OR = 0.66; 95% CI 
0.34–1.28); Significant risk reduction between regu-
lar use and non-small cell carcinoma of the lung (OR 
= 0.39; 95% CI 0.16–0.96)
Harris et al [23] 2002 (US) Case-control 
study
489 lung cancer patients and 978 
screening clinic controls (heavy 
smokers)
Significant risk reduction among daily aspirin users 
(OR = 0.32; 95% CI 0.23–0.44); effect seen among 
men and women
Current study 2002 (US) Hospital-based 
case-control 
study
868 lung cancer cases and 935 hos-
pital controls with non-neoplastic 
conditions
Significant risk reduction among regular aspirin 
users (OR = 0.57; 95% CI 0.41–0.78); effect seen 
among men and womenBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/31
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ductions were observed for both NSCLC (adjusted OR=
0.62; 95% CI 0.45–0.86) and small cell lung cancer
(SCLC) (adjusted OR = 0.32; 95% CI 0.16–0.63).
Conclusions
Results from this hospital-based case control study are
largely consistent with the existing body of evidence on
the association between regular aspirin use and lung can-
cer risk. All previous studies reported some evidence of re-
duced risk of lung cancer in relation to use aspirin or other
NSAIDs [14,17–23] . We observed a significant risk reduc-
tion among participants defined as regular users in the to-
tal sample, as well as among men and women separately.
Our data also demonstrated significant risk reductions as-
sociated with higher aspirin doses, prolonged duration,
and greater tablet years of aspirin use, although significant
trends were largely restricted to male participants. We fur-
ther observed that, after restricting the analyses to current
and former smokers, the chemoprotective effect of aspirin
was most apparent among individuals in the lower tertile
of the packyear distribution. Finally, when we explored
this risk association among histological subtypes, signifi-
cant risk reductions were apparent in when controls were
compared to patients with both NSCLC and SCLC.
Table 2: Characteristics of 868 lung cancer patients and 935 hos-
pital-based controls – Roswell Park Cancer Institute, 1982–1998.
Cases 
(n = 868)
Controls
(935)
p value
Age (years)1 62.10 (8.76) 61.59 (9.11) ns
Sex2
Female 335 (38.6%) 358 (38.3%)
Male 533 (61.4%) 577 (61.7%) ns
Education2
Up to high 
school
629 (72.5%) 498 (53.3%)
College 231 (26.6%) 431 (46.1%)
Unknown 8 (0.9%) 6 (0.6%) p < 0.001
Smoking 
Status2
Current 212 (24.4%) 137 (14.7%)
Former 611 (70.4%) 425 (45.5%)
Never 45 (5.2%) 373 (39.8%) p < 0.001
Packyears1,3 58.74 (37.55) 21.35 (27.23) p < 0.001
1 Mean (SD); differences in means detected using independent t-tests 2 
n (%); differences in proportions detected using chi-square tests 3 
Packs per day × years of smoking
Table 3: Risk of lung cancer in association with aspirin use – Roswell Park Cancer Institute, 1982–1998.
Total Sample Females Males
Cases
 (n = 868)
Controls
 (n = 935)
Adjusted OR1 
(95% CI)
Cases
 (n = 335)
Controls
 (n = 358)
Adjusted OR1 
(95% CI)
Cases
 (n = 533)
Controls
 (n = 577)
Adjusted OR1 
(95% CI)
Non-User 747 768 1.0 299 306 1.0 448 462 1.0
Regular User2 121 167 0.57 
(0.41–0.78)
36 52 0.52 
(0.29–0.95)
85 115 0.62 
(0.43–0.90)
1–6 tablets/week 26 41 0.53 
(0.28–0.99)
92 6 0 . 1 7  
(0.05–0.50)
17 15 1.01 
(0.46–2.59)
7+ tablets/week 95 126 0.58 
(0.41–0.82)
27 26 0.88 
(0.43–1.79)
68 100 0.56 
(0.37–0.83)
p = 0.04 p = 0.19 p = 0.006
1–10 years of use 90 126 0.56 
(0.39–0.79)
23 38 0.42 
(0.21–0.86)
67 88 0.65 
(0.43–0.98)
11+ years of use 31 41 0.61 
(0.34–1.09)
13 14 0.88 
(0.30–2.55)
18 27 0.53 
(0.26–1.10)
p = 0.06 p = 0.11 p = 0.01
1–10 tablet years3 84 106 0.63 
(0.44–0.92)
20 30 0.47 
(0.22–0.99)
64 76 0.73 
(0.48–1.12)
11+ tablet years 37 61 0.45 
(0.27–0.77)
16 22 0.61 
(0.24–1.54)
21 39 0.40 
(0.21–0.78)
p < 0.001 p = 0.07 p = 0.004
1 Odds ratio adjusted for age, education, and packyears of cigarettes 2 Regular use was defined as self-reported use at least once a week for at least 
one year 3 Tablets per day × years of useBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/31
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Although our findings follow the general trend that has
been demonstrated in previous investigations, some dif-
ferences exist. Two cohort studies reported reduced risk
among aspirin users among females, but not males
[18,19], while we observed strongest associations for male
participants. Another study did not demonstrate a risk re-
duction among females [20], whereas we consistently
found non-significant risk estimates below unity for fe-
male participants. In a recent report based on the NYU
Women's Health Study, Akhmedkhanov et al. [22] report-
ed a significant risk reduction for NSCLC and a more
modest, non-significant decease in risk for all histological
types of lung cancer. Our data are partly in contrast to
these results, in that we observed the most marked reduc-
tion for SCLC, but also a significant decrease in risk for all
NSCLC subtypes combined.
These discrepancies in results may be partly explained by
differences in study designs across studies (i.e., rand-
omized trial [17], cohort study [14,18,19,22] case-control
study [20,23], or by the vast differences in exposure as-
sessment, ranging from assignment of participants to aspi-
rin intervention group vs. placebo group [17] over ever
use of aspirin in the last 30 days [14] to having had an
NSAID prescription in the past three years [21].
One of the proposed mechanisms for the chemopreven-
tive properties of aspirin and other NSAIDs points to the
observation that NSAIDs inhibit prostaglandin (PG)-en-
doperoxide synthase (cyclooxygenase) enzymes [24], of
which two forms of similar enzymatic activity exist, COX-
1 and COX-2. COX-1 is constitutively expressed and in-
volved in homeostasis [24]; COX-2 is induced and in-
volved in inflammation [24,25]. There is evidence from
laboratory studies to suggest that the COX-2 pathway may
be involved in lung tumorigenesis. Bauer et al. [26] report-
ed significantly higher levels of COX-2 enzymes in mouse
lung tumor tissue compared to normal tissue. It has also
been shown that aspirin inhibited nitrosamine induced
lung carcinogenesis [27], and it reduced COX-2 enzyme
levels in lung cancer cell lines [28]. Further support for a
potential role of the COX-2 pathway in lung cancer devel-
opment comes from several investigations that demon-
strated COX-2 overexpression in human lung tumors,
specifically NSCLC [29–32] and precursor lesions [33].
While COX-2 expression was generally shown to be in-
creased in NSCLC and to a much lesser extent in SCLC, the
role of COX-2 expression in latter tumor type is difficult
to determine, due to the fact that the numbers of SCLC tu-
mors examined in these studies was very small.
Table 4: Risk of lung cancer in association with aspirin use among current and former smokers – Effect of packyears of cigarettes smoked 
– Roswell Park Cancer Institute, 1982–1998.
Lower tertile of packyear distribution
 (1 – 34 packyears)
Middle tertile of packyear distribution
 (34.1 – 60 packyears)
Upper tertile of packyear distribution
 (60.1 – 260 packyears)
Cases
 (n = 162)
Controls
 (n = 288)
Adjusted OR1 
(95% CI)
Cases
 (n = 307)
Controls
 (n = 157)
Adjusted OR1 
(95% CI)
Cases
 (n = 336)
Controls
 (n = 90)
Adjusted OR1 
(95% CI)
Non-User 149 238 1.0 264 127 1.0 278 68 1.0
Regular User2 13 50 0.43 
(0.22–0.83)
43 30 0.70 
(0.41–1.18)
58 22 0.66 
(0.37–1.16)
1–6 tablets/week 2 10 0.32 
(0.07–1.53)
750 . 6 2  
(0.19–2.05)
16 2 2.02 
(0.45–9.04)
7+ tablets/week 11 40 0.45 
(0.22–0.92)
36 25 0.71 
(0.40–1.26)
42 20 0.52 
(0.28–0.95)
p = 0.02 p = 0.20 p = 0.06
1–10 years of use 10 35 0.47 
(0.22–0.99)
33 23 0.66
 (0.37–1.19)
44 16  0.68 
(0.36–1.29)
11+ years of use 3 15 0.32 
(0.09–1.16)
10 7 0.83 
(0.30–2.29)
14 6 0.59 
(0.22–1.61)
p = 0.01 p = 0.26 p = 0.15
1–10 tablet 
years3
10 27 0.60 
(0.28–1.30)
33 22 0.70 
(0.38–1.26)
38 12 0.78 
(0.38–1.58)
11+ tablet years 3 23 0.22 
(0.06–0.75)
10 8 0.70 
(0.26–1.86)
20 10 0.51 
(0.22–1.15)
p = 0.006 p = 0.21 p = 0.09
1 Odds ratio adjusted for age and education 2 Regular use was defined as self-reported use at least once a week for at least one year 3 Tablets per 
day × years of useBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/31
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Several methodological issues should be considered in in-
terpreting these results. As in all case-control studies, bias
could have affected the validity of the current findings. Se-
lection bias is likely to have occurred in this investigation.
The lung cancer patient group was restricted to individuals
who were treated at RPCI, a large regional cancer treat-
ment center, and are not likely to represent the general
population of lung cancer patients in the western New
York region. However, it is unlikely that self-reported as-
pirin use would be different for RPCI patients than from
patients treated in different facilities. The use of hospital
controls might introduce bias, due to the possibility that
some controls were suffering from conditions that would
make them more likely to use aspirin . However, greater
likelihood of aspirin use in the control group would only
have attenuated the true risk estimate, rather than pro-
duced spurious associations. In addition, hospital con-
trols were selected from a large pool of eligible
participants with a wide variety of non-cancer diagnostic
groups, minimizing bias arising from potential overrepre-
sentation of patients with characteristics that may be asso-
ciated with the exposures. In fact, no significant
differences with respect to aspirin use were observed for
the most common diagnostic categories among controls.
Selection bias may have also been introduced due to the
low participation rate in this study. Only about 50 percent
of eligible cases and controls agreed to complete the PEDS
questionnaire. We have no way of ascertaining whether or
not those individuals who refused to complete the instru-
ment differed from participants with respect to aspirin
use. Nevertheless, previous studies that utilized the PEDS
data base and faced the same methodological issue, con-
sistently replicated established epidemiological associa-
tions for a variety of cancer sites, including ovary [34,35],
colon [36], breast [37], prostate [38], and lung [39]. Recall
bias is always a problem in case-control studies of cancer.
However, in this investigation it may have been less of an
issue, due to our use of hospital controls. Further, the
questionnaire used in this investigation places no particu-
lar emphasis on any specific item. Thus, there is little rea-
son to believe that cases were more motivated than
controls to recall aspirin use. Exposure misclassification
may also have affected our results, as we based our analy-
ses on self-reported analgesic use and were not able to in-
dependently verify this information. Also, the
questionnaire did not assess the specific doses of analgesic
preparations, such as regular or extra-strength tablets. Fur-
ther, we did not have detailed information on other
NSAIDs that participants may have taken and cannot rule
out the possibility that cases may have been more likely to
have taken preparations such as ibuprofen or prescription
NSAIDs, which would have resulted in an overestimated
or entirely spurious results. However, we have no reason
to believe that any of these potential sources of misclassi-
fication were differential in nature.
In summary, in this hospital-based case-control study of
lung cancer, we observed consistent associations between
aspirin use and risk, particularly among men. Although a
number of epidemiological studies have produced fairly
consistent results, none of these investigations has been
specifically designed to address this research question.
These suggestive findings need to be replicated by a well-
designed pharmacoepidemiological study that incorpo-
rates the newly introduced NSAID preparations.
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